AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
28.96
-0.31 (-1.06%)
Apr 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 28.88 - 29.76
52 week 27.68 - 35.33
Open 29.73
Vol / Avg. 0.00/3.79M
Mkt cap 71.79B
P/E 25.94
Div/yield 0.95/4.83
EPS 1.12
Shares 1.26B
Beta 0.76
Inst. own 19%
Jun 6, 2016
AstraZeneca PLC Analysts and Investors Briefing during the American Society of Clinical Oncology (ASCO) Annual Meeting - 7:30PM EDT - Add to calendar
Apr 29, 2016
AstraZeneca PLC Annual Shareholders Meeting
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Call
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Release
Mar 31, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Investor Relations Insights Conference
Mar 18, 2016
AstraZeneca PLC at Carnegie Healthcare Seminar
Mar 15, 2016
AstraZeneca PLC at Barclays Global Healthcare Conference
Mar 15, 2016
AstraZeneca PLC at Exane Bnp Healthcare Conference
Mar 7, 2016
AstraZeneca PLC at Cowen Health Care Conference
Mar 2, 2016
AstraZeneca PLC at Credit Suisse One-on-One Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.63% 11.44%
Operating margin 17.00% 16.65%
EBITD margin - 28.89%
Return on average assets 5.67% 4.76%
Return on average equity 18.09% 14.82%
Employees 61,500 -
CDP Score - 97 B

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Bio & Compensation  - Reuters
Fiona Cicconi Executive Vice-President, Human Resources
Bio & Compensation  - Reuters
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Luke Miels Executive Vice-President, GPPS
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters